Cyclic boronates as versatile scaffolds for KPC-2 β-lactamase inhibition [PDF]
, 2020 Klebsiella pneumoniae carbapenemase-2 (KPC-2) is a serine-β-lactamase (SBL) capable of hydrolysing almost all β-lactam antibiotics. We compare KPC-2 inhibition by vaborbactam, a clinically-approved monocyclic boronate, and VNRX-5133 (taniborbactam), a ...
Brem, Jürgen +6 more
core +3 more sources
Antibiotics, 2022 The role of β-lactamases in reduced susceptibility or resistance to cefiderocol has been supported by recent reports. The purpose of this study was to investigate the in vitro impact of clinically available β-lactamase inhibitors on cefiderocol activity ...
Gabriele Bianco +7 more
doaj +1 more source
Rapid meropenem/vaborbactam NP test for detecting susceptibility/resistance in Enterobacterales [PDF]
Journal of Antimicrobial Chemotherapy, 2023 Abstract Background The treatment options for infections caused by carbapenem-resistant Enterobacterales (CRE) are extremely scarce nowadays and the development of new antibiotics does not follow the exponential increase in the dissemination of carbapenem resistance determinants worldwide.
Patrice Nordmann +5 more
openaire +2 more sources
The continued value of disk diffusion for assessing antimicrobial susceptibility in clinical laboratories: Report from the Clinical and Laboratory Standards Institute Methods Development and Standardization Working Group [PDF]
, 2018 Expedited pathways to antimicrobial agent approval by the U.S. Food and Drug Administration (FDA) have led to increased delays between drug approval and the availability of FDA-cleared antimicrobial susceptibility testing (AST) devices.
Burnham, Carey-Ann D +6 more
core +2 more sources
Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against KPC-Producing K. pneumoniae Collected from Bacteremic Patients, 2018 to 2020 [PDF]
, 2022 The management of KPC-producing K. pneumoniae (KPC-Kp) in bloodstream infections (BSIs) represent a serious clinical challenge. In this study, the aim is to assess the incidence of resistance to novel β-lactams-β-lactamase inhibitor combinations (βL ...
Ambretti S +4 more
core +1 more source
The 2018 Garrod Lecture: Preparing for the Black Swans of Resistance [PDF]
, 2018 The need for governments to encourage antibiotic development is widely agreed, with ‘Market Entry Rewards’ being suggested. Unless these are to be spread widely – which is unlikely given the $1 billion sums proposed– we should be wary, for this approach ...
Livermore, David
core +1 more source
Antibiotics, 2023 Background: Avibactam, relebactam and vaborbactam are β-lactamase inhibitors that proved their efficiency against KPC-producing Enterobacterales. Regarding their inhibitor activity towards Ambler’s class A extended spectrum β-lactamases (ESBL) and Ambler’
Rémy A. Bonnin +6 more
doaj +1 more source
Management of KPC-Producing Klebsiella pneumoniae Infections [PDF]
, 2015 Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-KP) has become one of the most important contemporary pathogens, especially in endemic ...
M. Bassetti +142 more
core +2 more sources
Profiling interactions of vaborbactam with metallo-β-lactamases [PDF]
Bioorganic & Medicinal Chemistry Letters, 2019 β-Lactams are the most successful antibacterials, yet their use is threatened by resistance, importantly as caused by β-lactamases. β-Lactamases fall into two mechanistic groups: the serine β-lactamases that utilise a covalent acyl-enzyme mechanism and the metallo β-lactamases that utilise a zinc-bound water nucleophile.
Langley, G +11 more
openaire +7 more sources
Antimicrobial-resistant Gram-negative infections in neonates: burden of disease and challenges in treatment. [PDF]
, 2017 PURPOSE OF REVIEW: This review summarizes the main challenges of antimicrobial resistance (AMR) in the neonatal population with a special focus on multidrug-resistant (MDR) Gram-negative pathogens.
Bielicki, J +3 more
core +1 more source